TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04572646

Intervention type: OTHER
Group type: OTHER
Intervention: NRT proposition and exhaled CO measurement
Description: Nicotine replacement therapy is proposed to every patient included in the study.~Whether the patient accepts the therapy or not, exhaled carbon monoxide is measured at the preoperative consultation (about 15 days before surgery) and the day of surgery by a nurse. These two measures are compared to assess efficacy of nicotine replacement therapy.
Study: NCT02797756

Intervention type: PROCEDURE
Intervention: Esophago-gastro-duodenoscopy (EGD) with biopsy

Intervention type: PROCEDURE
Intervention: Esophago-gastro-duodenoscopy (EGD) with biopsy

Intervention type: PROCEDURE
Intervention: Esophageal Impedance Monitoring (EIM)

Intervention type: PROCEDURE
Intervention: Esophageal Impedance Monitoring (EIM)
Study: NCT00118274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melanoma helper peptide vaccine
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melanoma helper peptide vaccine
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid helper peptide
Description: Given intradermally and subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid helper peptide
Description: Given intradermally and subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT01029912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulator
Description: 6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulator
Description: 6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device.
Study: NCT01065025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-205
Description: Repeated ascending oral doses of 4SC-205.
Study: NCT04588636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral and self-care therapy
Description: It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: behavioral and self-care therapy
Description: It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral and self-care therapy
Description: It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral and self-care therapy
Description: It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rigid occlusal splint (ROS)
Description: Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft occlusal splint (SOS)
Description: Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-occlusive splint (NOS)
Description: non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
Study: NCT01285024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitagel
Description: Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
Study: NCT04365426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical stimulus
Description: Electrical dynamometer to measure mechanical pressure
Study: NCT02501902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
Study: NCT02518776

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological tests
Description: Neuropsychological tests
Study: NCT04060810

Intervention type: OTHER
Group type: OTHER
Intervention: MR CSF flowmetry
Description: MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
Study: NCT03027388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100
Description: LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.
Study: NCT04169685

Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: during flexible bronchoscopy

Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: during flexible bronchoscopy
Study: NCT03515018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: pulse therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: 400mg qd PO per day
Study: NCT02760160

Intervention type: OTHER
Group type: OTHER
Intervention: Reconstituted grape powder
Description: To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) \[114, 217, 343, 500, 619, 848\].
Study: NCT00734812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy
Description: Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
Study: NCT00916097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL(XRP6976)
Description: docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
Study: NCT04920019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic continuous epidural analgesia
Description: Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic continuous epidural analgesia
Description: Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)
Study: NCT01753505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 64-slice Multidetector coronary CT angiography
Study: NCT02367937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-4016 (icosabutate)
Description: Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description
Study: NCT00508716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy-Tailored Education
Description: Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
Study: NCT01858389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
Study: NCT01269463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride Extended Release Capsule
Description: An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride Extended Release Capsule
Description: An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule without active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule without active drug
Study: NCT00750815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
Description: Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
Description: Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
Study: NCT01125267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multifamily group-adherence
Description: multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
Study: NCT00734812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total laparoscopic hysterectomy
Description: Patients will be randomized to either removal or retention of cervix
Study: NCT04745078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caboxy30
Description: carboxy30 to periorbital dark halos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caboxy60
Description: carboxy60 to periorbital dark halos
Study: NCT04146519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Autologous mesenchymal stem cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT04365426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical stimulus
Description: Electrical dynamometer to measure mechanical pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal (cold) stimulus
Description: Water cold bath

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal (cold) stimulus
Description: Water cold bath

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC)
Description: Oral contraceptive (OC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No oral contraceptive (No OC)
Description: No oral contraceptive (No OC)
Study: NCT03771040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04463940

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02153437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-919373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-919373
Study: NCT02775630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
Study: NCT00570323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex
Description: Aromatase inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex
Description: Aromatase inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faslodex
Description: Hormone Receptor
Study: NCT02056028

Intervention type: PROCEDURE
Intervention: Hepatic resection
Study: NCT04406402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute dietary protocols and lifestyle modification
Description: The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute dietary protocols and lifestyle modification
Description: The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute dietary protocols and lifestyle modification
Description: The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute dietary protocols and lifestyle modification
Description: The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute dietary protocols and lifestyle modification
Description: The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute dietary protocols and lifestyle modification
Description: The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
Study: NCT05357768

Intervention type: OTHER
Intervention: data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue
Description: Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification.

Intervention type: OTHER
Intervention: data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue
Description: Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification.
Study: NCT01905189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resynchronization therapy of right ventricle
Description: Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
Study: NCT04164810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
Study: NCT03929432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation with SLT
Description: Soterix Medical 1×1 transcranial Direct Current Stimulator for Clinical Trials (1x1 tDCS-CT).~Excitatory stimulation to the left hemisphere will be achieved through a 1x1 montage utilizing two carbon-rubber electrodes and 5x7 EASY pad sponges (A-tDCS \[excitatory\]left target; C-tDCS \[inhibitory\]right hemisphere). Each PWA will have a unique 5-digit tDCS program code for each treatment phase. One code will instruct the 1x1 tDCS-CT to administer active stimulation as describe above (i.e., 1.5 mA for 20 min). The other will administer 1.5 mA for only a few seconds to simulate active stimulation. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation with SLT
Description: Control condition in which only SLT is administered.Participant receives 1.5 mA for only a few seconds to simulate active stimulation, then the stimulation will cease. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment